CVE:EMH

Emerald Health Therapeutics Competitors

C$0.26
-0.03 (-8.62 %)
(As of 04/12/2021 03:59 PM ET)
Add
Compare
Today's Range
C$0.27
Now: C$0.27
C$0.30
50-Day Range
C$0.27
MA: C$0.30
C$0.36
52-Week Range
C$0.15
Now: C$0.27
C$0.53
Volume295,818 shs
Average Volume713,450 shs
Market CapitalizationC$54.33 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Emerald Health Therapeutics (CVE:EMH) Vs. IPA, HBP, ACST, NVH, MBX, and PDP

Should you be buying EMH stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Emerald Health Therapeutics, including ImmunoPrecise Antibodies (IPA), Helix BioPharma (HBP), Acasti Pharma Inc. (ACST.V) (ACST), Novoheart (NVH), Microbix Biosystems (MBX), and Pediapharm (PDP).

Emerald Health Therapeutics (CVE:EMH) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Emerald Health Therapeutics and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
ImmunoPrecise Antibodies0000N/A

Profitability

This table compares Emerald Health Therapeutics and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Valuation and Earnings

This table compares Emerald Health Therapeutics and ImmunoPrecise Antibodies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38
ImmunoPrecise AntibodiesC$17.18 million16.98C$-4,082,906.00C($0.21)-71.45

ImmunoPrecise Antibodies has higher revenue and earnings than Emerald Health Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

ImmunoPrecise Antibodies beats Emerald Health Therapeutics on 4 of the 5 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Emerald Health Therapeutics and Helix BioPharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Helix BioPharma0000N/A

Profitability

This table compares Emerald Health Therapeutics and Helix BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
Helix BioPharmaN/AN/AN/A

Valuation and Earnings

This table compares Emerald Health Therapeutics and Helix BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38
Helix BioPharmaN/AN/AN/AC($0.06)-15.09

Helix BioPharma has lower revenue, but higher earnings than Emerald Health Therapeutics. Helix BioPharma is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Emerald Health Therapeutics beats Helix BioPharma on 2 of the 3 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Acasti Pharma Inc. (ACST.V) (CVE:ACST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Emerald Health Therapeutics and Acasti Pharma Inc. (ACST.V), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Acasti Pharma Inc. (ACST.V)0000N/A

Profitability

This table compares Emerald Health Therapeutics and Acasti Pharma Inc. (ACST.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
Acasti Pharma Inc. (ACST.V)N/AN/AN/A

Valuation and Earnings

This table compares Emerald Health Therapeutics and Acasti Pharma Inc. (ACST.V)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38
Acasti Pharma Inc. (ACST.V)C$81,000.001,581.20C$6.80 millionC$0.0318.82

Acasti Pharma Inc. (ACST.V) has lower revenue, but higher earnings than Emerald Health Therapeutics. Emerald Health Therapeutics is trading at a lower price-to-earnings ratio than Acasti Pharma Inc. (ACST.V), indicating that it is currently the more affordable of the two stocks.

Summary

Acasti Pharma Inc. (ACST.V) beats Emerald Health Therapeutics on 4 of the 5 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Emerald Health Therapeutics and Novoheart, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Novoheart0000N/A

Profitability

This table compares Emerald Health Therapeutics and Novoheart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
NovoheartN/AN/AN/A

Valuation and Earnings

This table compares Emerald Health Therapeutics and Novoheart's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95

Novoheart has lower revenue, but higher earnings than Emerald Health Therapeutics. Novoheart is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Novoheart beats Emerald Health Therapeutics on 3 of the 5 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Emerald Health Therapeutics and Microbix Biosystems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Microbix Biosystems0000N/A

Profitability

This table compares Emerald Health Therapeutics and Microbix Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
Microbix BiosystemsN/AN/AN/A

Valuation and Earnings

This table compares Emerald Health Therapeutics and Microbix Biosystems' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38
Microbix BiosystemsC$11.64 million5.83C$-5,581,797.00C($0.05)-12.16

Microbix Biosystems has lower revenue, but higher earnings than Emerald Health Therapeutics. Microbix Biosystems is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Microbix Biosystems beats Emerald Health Therapeutics on 3 of the 5 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Pediapharm (CVE:PDP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Emerald Health Therapeutics and Pediapharm, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Pediapharm0000N/A

Profitability

This table compares Emerald Health Therapeutics and Pediapharm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
PediapharmN/AN/AN/A

Valuation and Earnings

This table compares Emerald Health Therapeutics and Pediapharm's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11

Pediapharm has lower revenue, but higher earnings than Emerald Health Therapeutics. Pediapharm is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Pediapharm beats Emerald Health Therapeutics on 3 of the 5 factors compared between the two stocks.


Emerald Health Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IPA
ImmunoPrecise Antibodies
0.4$15.29-0.8%C$123.03 millionC$17.18 million-71.45
HBP
Helix BioPharma
0.5$0.83-10.8%C$117.14 millionN/A-15.09
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.64-6.3%C$88.79 millionC$81,000.0018.82News Coverage
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.62-11.3%C$67.86 millionC$11.64 million-12.16High Trading Volume
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
PMN
ProMIS Neurosciences
0.5$0.22-4.7%C$65.78 millionC$1,787.00-10.75
SBM
Sirona Biochem
0.5$0.35-8.6%C$58.80 millionC$123,870.00-26.92Gap Up
COV
Covalon Technologies
0.6$1.41-0.7%C$37.44 millionC$23.84 million-5.92
IGX
IntelGenx Technologies
0.9$0.66-13.6%C$30.87 millionC$1.54 million-10.15High Trading Volume
News Coverage
QPT
Quest PharmaTech
0.8$0.11-0.0%C$21.76 millionC$38,871.000.17High Trading Volume
Gap Down
CZO
Ceapro
0.6$0.79-8.9%C$21.65 millionC$16.14 million23.94
CTX
Crescita Therapeutics
0.6$0.85-1.2%C$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.16-6.3%C$14.12 millionC$1.34 million-4.57
GSD
Devonian Health Group
0.5$0.27-3.7%C$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09-5.6%C$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06-0.0%C$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60-0.0%C$10.80 millionC$12.71 million-1.03Gap Up
BTI
Bioasis Technologies
0.7$0.44-11.4%C$10.16 millionC$4.12 million40.00
HEM
Hemostemix
0.6$0.48-2.1%C$9.07 millionN/A-2.86
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.36-1.4%C$6.94 millionC$5.60 million6.67
IOT
Innovotech
0.8$0.15-3.3%C$6.52 millionC$1.04 million75.00
BCT
BriaCell Therapeutics
0.5$4.90-30.6%C$4.48 millionN/A-1.58High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5$2.95-2.7%C$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.20
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.